THE 2006 ACT SAFETY & EFFICACY AUDIT

The 2006 ACT Safety and Efficacy Audit has recently been completed. The audit involved +730 participants treated from 2002 - 2006. The data resulting from this audit has been compiled into a white paper to be posted on the ACT site within the week. Each individual treatment is detailed in the following +730 Treatment Audit Forms, for third party access and verification of study data. Study results show NO MAJOR ADVERSE EFFECTS reported from the therapy and Objective Rating Scale (ORS). Scores (rated 0 - 20) which reveal some form of significant clinical benefit in over 60% of total treatments and estimated 80% of Multiple Sclerosis treatments with a large percentage of reported benefits sustaining over the one year mark.

Treatment Audit Forms: Page 1

Page 1 2 3 4 5 6 7 8

• ID#_791_RR_MS_ORS_3
  
  
• ID#_741_PP_MS_ORS_1
  
  
• ID#_738_Unspecified_MS_ORS_3
  
  
• ID#_737_PP_MS_ORS_8
  
  
• ID#_735_PP_MS_ORS_3
  
  
• ID#_733_RR_MS_ORS_18
  
  
• ID#_731_HIE_ORS_3
  
  
• ID#_730_SP_MS_ORS_2
  
  
• ID#_729_SP_MS_ORS_11
  
  
• ID#_728_SP_MS_ORS_11
  
  
• ID#_727_PP_MS_ORS_11
  
  
• ID#_726_Unspecified_MS_ORS_18
  
  
• ID#_724_Unspecified_MS_ORS_1
  
  
• ID#_723_SP_MS_ORS_11
  
  
• ID#_722_OO_MS_ORS_12
  
  
• ID#_721_SCI_ORS_6
  
  
• ID#_720_SP_MS_ORS_1
  
  
• ID#_718_RR_MS_ORS_7
  
  
• ID#_717_SP_MS_ORS_1
  
  
• ID#_716_RR_MS_ORS_0
  
  
• ID#_715_RR_MS_ORS_9
  
  
• ID#_714_PD_ORS_10
  
  
• ID#_711_Ataxia_ORS_6
  
  
• ID#_710_ALS_ORS_0
  
  
• ID#_709_UNSPECIFIED_SCLERODERMA_ORS_0
  
  
• ID#_708_UNSPECIFIED_MS_ORS_0
  
  
• ID#_707_SP_MS_ORS_0
  
  
• ID#_706_RR_MS_ORS_0
  
  
• ID#_705_PP_MS_ORS_1
  
  
• ID#_704_SP_MS_ORS_7
  
  
• ID#_703_CBD_ORS_3
  
  
• ID#_702_SP_MS_ORS_8
  
  

Page 1 2 3 4 5 6 7 8